Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.71 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | DRD4 | P21917 | 8/20 | 0.44 |
| ▸ | DRD2 | P14416 | 4/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4467283 | 1.00 | GSK3B (0.71) | GSK3BPTPN1LMNAPTBP1SMN1; SMN2 | |
| SCHEMBL6811236 | 0.83 | TRPA1 (0.49) | GSK3BLMNAPTBP1SMN1; SMN2DRD4 | |
| SCHEMBL7871655 | 0.83 | GSK3B (0.73) | GSK3BLMNADRD4DRD2SLC6A4 | |
| SCHEMBL13142483 | 0.83 | GSK3B (0.73) | GSK3BLMNAALDH1A1GAA | |
| SCHEMBL3612594 | 0.83 | GSK3B (0.73) | GSK3BLMNAALDH1A1GAA | |
| SCHEMBL16539522 | 0.81 | GSK3B (0.71) | GSK3BLMNASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL437419 | 0.81 | GSK3B (0.70) | GSK3BPTPN1LMNADRD4DRD2 | |
| SCHEMBL434112 | 0.81 | GSK3B (0.70) | GSK3BPTPN1LMNADRD4DRD2 | |
| SCHEMBL28778258 | 0.81 | GSK3B (0.70) | GSK3BPTPN1LMNADRD4DRD2 | |
| SCHEMBL13147671 | 0.79 | SLC6A4 (0.47) | GSK3BLMNAPTBP1SMN1; SMN2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504501-B2 | Antiprotozoal imidazopyridine compounds | MERIAL LIMITED (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504501-B2 | Antiprotozoal imidazopyridine compounds | MERIAL LIMITED (US) | 2009-03-17 | — | — | US | disclosed |
| US-7504501-B2 | Antiprotozoal imidazopyridine compounds | MERIAL LIMITED (US) | 2009-03-17 | — | — | US | disclosed |
| US-7429590-B2 | Antiprotozoal imidazopyridine compounds | MERCK & CO. INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429590-B2 | Antiprotozoal imidazopyridine compounds | MERCK & CO. INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-20060293303-A1 | Antiprotozoal imidazopyridine compounds | MERCK SHARP & DOHME LLC | 2006-12-28 | — | — | US | disclosed |
| US-20060178358-A1 | Antiprotozoal imidazopyridine compounds | MERIAL, INC. | 2006-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293303-A1 | Antiprotozoal imidazopyridine compounds | PNPO, PIR, PNP | GSK3B 3381/4885PTPN1 596/4885LMNA 1135/4885 |
| US-20060178358-A1 | Antiprotozoal imidazopyridine compounds | PNPO, PIR, TYMP | GSK3B 3148/4885PTPN1 1528/4885LMNA 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.